Ranbaxy, Teva settle with New York State

Share this article:

Ranbaxy, Teva and the State of New York settled a dispute that alleges the two generic drugmakers colluded not to challenge each other's right to produce no-name versions of Pfizer's cholesterol-lowering medication Lipitor as well as other medications.

“Agreements between drug manufacturers to protect each other's market positions violate principles of antitrust law, and can lead to higher drug prices,” New York Attorney General Eric Schneiderman said in a statement, as quoted by Bloomberg.

Bloomberg reports that neither company admitted wrongdoing, but the two are forwarding a total of $300,000 to the State of New York to settle the allegations.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.